Jaguar Health Advances Crofelemer for Intestinal Failure Diseases

Jaguar Health, Inc. has announced a strategic focus on rare intestinal failure diseases supported by non-dilutive funds from the closing of a license deal for Mytesi and Canalevia-CA1 in the US. The company received an initial $16 million payment with the potential for an additional $22 million from milestones and future payments. The funds will advance the development of crofelemer, an oral solution targeting short bowel syndrome and microvillus inclusion disease (MVID).

Crofelemer has shown significant results in reducing parenteral support in pediatric patients, decreasing dependency by 12 to 37% in an ongoing study. This reduction could extend and save lives, addressing the harsh outcomes of current supportive treatments. Jaguar aims to achieve Breakthrough Therapy designation from the FDA, which could expedite crofelemer's market approval, supported by promising findings and ongoing clinical trials.